Ornipressin

Ornipressin
Names
	IUPAC name (2S)-N-[(2S)-5-Amino-1-[(2-amino-2-oxoethyl)amino]- 1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)- 19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl] -6,9,12,15,18-pentaoxo-13-(phenylmethyl)1,2-dithia-5,8,11,14,17- pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
Identifiers
CAS Number	3397-23-7 ;
3D model (JSmol)	Interactive image;
ChemSpider	16736525 ;
ECHA InfoCard	100.020.231
MeSH	Ornipressin
PubChem CID	14257660;
UNII	1KTH6N080W ;
	InChI InChI=1S/C45H63N13O12S2/c46-16-4-8-28(39(64)51-21-37(50)62)53-44(69)34-9-5-17-58(34)45(70)33-23-72-71-22-27(47)38(63)54-30(19-25-10-12-26(59)13-11-25)42(67)55-31(18-24-6-2-1-3-7-24)41(66)52-29(14-15-35(48)60)40(65)56-32(20-36(49)61)43(68)57-33/h1-3,6-7,10-13,27-34,59H,4-5,8-9,14-23,46-47H2,(H2,48,60)(H2,49,61)(H2,50,62)(H,51,64)(H,52,66)(H,53,69)(H,54,63)(H,55,67)(H,56,65)(H,57,68)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1 Key: MUNMIGOEDGHVLE-LGYYRGKSSA-N ; InChI=1/C45H63N13O12S2/c46-16-4-8-28(39(64)51-21-37(50)62)53-44(69)34-9-5-17-58(34)45(70)33-23-72-71-22-27(47)38(63)54-30(19-25-10-12-26(59)13-11-25)42(67)55-31(18-24-6-2-1-3-7-24)41(66)52-29(14-15-35(48)60)40(65)56-32(20-36(49)61)43(68)57-33/h1-3,6-7,10-13,27-34,59H,4-5,8-9,14-23,46-47H2,(H2,48,60)(H2,49,61)(H2,50,62)(H,51,64)(H,52,66)(H,53,69)(H,54,63)(H,55,67)(H,56,65)(H,57,68)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1 Key: MUNMIGOEDGHVLE-LGYYRGKSBZ;
	SMILES NC(=O)CNC(=O)[C@H](CCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H]4NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC4)CC(N)=O;
Properties
Chemical formula	C45H63N13O12S2
Molar mass	1042.19 g/mol
Pharmacology
ATC code	H01BA05 (WHO)
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	verify (what is ?)
	Infobox references

Ornipressin is a vasoconstrictor,[1][2] haemostatic and renal agent.

References

H. Fruhstofer, M.D., M. Heisler, M.D. (1994). "Dose-response relation of ornipressin with regard to vasoconstriction in human skin". Br. J. Anaesth. 73 (2): 220–224. doi:10.1093/bja/73.2.220.CS1 maint: multiple names: authors list (link)
Marc De Kock, MD, Pierre-Francois Laterre, MD, Patricia Andruetto, MD, Lionel Vanderessen, MD, Sylvie Dekrom, MD, Bernard Vanderick, MD and Patricia Lavand’homme, MD (June 2000). "Ornipressin (Por 8): An Efficient Alternative to Counteract Hypotension During Combined General/Epidural Anesthesia". Anesthesia & Analgesia. 90 (6): 1301–1307. doi:10.1097/00000539-200006000-00008.CS1 maint: multiple names: authors list (link)

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] H. Fruhstofer, M.D., M. Heisler, M.D. (1994). "Dose-response relation of ornipressin with regard to vasoconstriction in human skin". Br. J. Anaesth. 73 (2): 220–224. doi:10.1093/bja/73.2.220.CS1 maint: multiple names: authors list (link)

[2] Marc De Kock, MD, Pierre-Francois Laterre, MD, Patricia Andruetto, MD, Lionel Vanderessen, MD, Sylvie Dekrom, MD, Bernard Vanderick, MD and Patricia Lavand’homme, MD (June 2000). "Ornipressin (Por 8): An Efficient Alternative to Counteract Hypotension During Combined General/Epidural Anesthesia". Anesthesia & Analgesia. 90 (6): 1301–1307. doi:10.1097/00000539-200006000-00008.CS1 maint: multiple names: authors list (link)